제2형 당뇨병 환자에게 인크레틴 기반 약물치료요법

키워드

참고문헌 (36)

1. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
2. The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
3. Nathan DM, "Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 32, pp.193~203 (2009)
4. Wallace TM, "Use and abuse of HOMA modeling", Diabetes Care, 27, pp.1487~1495 (2004)
5. Kahn SE, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy", N Engl J Med, 355, pp.2427~2443 (2006)
6. Marchetti P, "Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control", Diabetes Care, 32(2), pp.S178~S183 (2009)
7. Nauck MA, "Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications", Am J Med, 124, pp.S3~S18 (2011)
8. Drab SR, "Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects", Pharmacotherapy, 30, pp.609~624 (2010)
9. Neumiller JJ, "Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus", Pharmacotherapy, 30, pp.463~484 (2010)
10. Rodbard HW, "Statement by an American Association of Clinical Endocrinologists", American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, 2009, pp.15, 540~559
11. Zarowitz BJ, "The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus", Pharmacotherapy, 29, pp.55S~67S (2009)
12. Buse JB, "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes", Diabetes Care, 27, pp.2628~2635 (2004)
13. DeFronzo RA, "Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes", Diabetes Care, 28, pp.1092~1100 (2005)
14. Kendall DM, "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea", Diabetes Care, 28, pp.1083~1091 (2005)
15. Nauck MA, "A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin : a non-inferity study", Diabetologia, 50, pp.259~267 (2007)
16. Kim D, "Effects of onceweekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes", Diabetes Care, 30, pp.1487~1493 (2007)
17. Drucker DJ, "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study", Lancet, 372, pp.1240~1250 (2008)
18. "FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program Website"[URL]
19. Garber A, "Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, paralled-treatment trial", Lancet, 373, pp.473~481 (2009)
20. Marre M, "Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)", Diabet Med, 26, pp.268~278 (2009)
21. Nauck M, "Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study", Diabetes Care, 32, pp.84~90 (2009)
22. Zinman B, "Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)", Diabetes Care, 32, pp.1224~1230 (2009)
23. Buse JB, "Liraglutide once a day versus exenatide twice a day for type 2 diabetes; a 26- week randomized, parallel-groul, multinational, open-label trial (LEAD-6)", Lancet, 374, pp.39~47 (2009)
24. Aschner P, "Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes", Diabetes Care, 29, pp.2632~2637 (2006)
25. Goldstein BJ, "Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes", Diabetes Care, 30, pp.1979~1987 (2007)
26. Raz I, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus", Diabetologia, 49, pp.2564~2571 (2006)
27. Rosenstock J, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study", Clin Ther, 28, pp.1556~1568 (2006)
28. DeFronzo RA, "The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone", Diabetes Care, 32, pp.1649~1655 (2009)
29. Rosenstock J, "Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drugnaive patients with type 2 diabetes", Diabetes Obes Metab, 10, pp.376~386 (2008)
30. Goodman M, "Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy", Horm Metab Res, 41, pp.368~373 (2009)
31. Pi-Sunyer FX, "Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes", Diabetes Res Clin Pract, 76, pp.132~138 (2007)
32. Rosenstock J, "Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes", Diabetes Obes Metab, 9, pp.175~185 (2007)
33. DeFronzo RA, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study", Diabetes Care, 31, pp.2315~2317 (2008)
34. Nauck MA, "Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study", Int J Clin Pract, 63, pp.46~55 (2009)
35. Pratley RE, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy", Diabetes Obes Metab, 11, pp.167~176 (2009)
36. Pratley RE, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study", Curr Med Res Opin, 25, pp.2361~2371 (2009)

관련 논문AI추천